SLDB Solid Biosciences Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Solid Biosciences Inc. (SLDB) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Updated corporate presentation published March 11, 2026 on Solid Biosciences' website
• Reg FD disclosure ensures institutional and retail investors receive simultaneous access to the same strategic update

+1 more insights

Item 8.01 · Other Events

• SGT-003 dosed 40 participants at 1E14vg/kg; Day 360 biopsy data (n=3) shows microdystrophin expression rising to 91% by western blot vs 60% at Day 90
• Key biomarker reductions at Day 90: CK -38%, ALT -43%, LDH -46%, plus 44% reduction in eMHC-positive fibers suggesting disruption of Duchenne's degeneration-regeneration cycle

+3 more insights

Other Solid Biosciences Inc. 8-K Filings

8-K Mar 6, 2026

Get deeper insights on Solid Biosciences Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.